20.5 C
Vientiane
Friday, October 24, 2025
spot_img
Home Blog Page 5

Govee Lights Up the Miami Dolphins’ Halloween Game at Hard Rock Stadium

Immersive outdoor lighting bring team pride and Halloween spirit to life

MIAMI, Oct. 23, 2025 /PRNewswire/ — Govee, a global leader in smart lighting innovation, is taking its official partnership with the Miami Dolphins to dazzling new heights. Before the Miami Dolphins matchup against the Baltimore Ravens at Hard Rock Stadium on October 30th, Govee will transform the fan experience inside the Dolphins Fan Zone with dynamic, vibrant lighting installations and activations designed to celebrate in aqua and orange.

Govee Lights Up the Miami Dolphins’ Halloween Game at Hard Rock Stadium
Govee Lights Up the Miami Dolphins’ Halloween Game at Hard Rock Stadium

“Lighting is more than decoration. It’s a way to express passion and connect with what you love,” said Eric Wu, CEO of Govee. “We are proud to empower Dolphins fans to brilliantly showcase their team pride and create an unforgettable game-day experience, both at the stadium and right at home.”

At the Hard Rock Stadium, Govee is set to unveil immersive experiences designed to connect fans through Govee outdoor lighting:

  • Touchdown Terrace – Outdoor Lighting Installation:

Featuring Govee’s signature Outdoor Lights, this installation will bring the Dolphins’ iconic colors to life through dynamic lighting scenes. Fans can experience firsthand how Govee’s smart outdoor lights can transform any area into a vibrant celebratory fan zone.

  • Fan Zone – Govee Booth & Interactive Activities:

At the Govee booth, fans can explore the brand’s latest smart lighting innovations, join exciting on-site activities, and take home exclusive Govee giveaways.

However, the excitement doesn’t stop at the Hard Rock Stadium. On October 27th, Govee will launch a special Home Makeover video featuring Miami Dolphins defensive back Elijah Campbell showing how he transforms his home with Govee’s outdoor lighting, adding a colorful Halloween twist that perfectly blends festive creativity with undeniable team pride.

About Govee

Govee has been revolutionizing the smart living experience with innovative, ambient lighting solutions since 2017. From living spaces, gaming setups, and outdoor areas, Govee’s smart home tech is not just visually stunning, but also functional – transforming small everyday moments into more personalized and brighter engaging lighting experiences. Embracing the idea that users should “Life is Colorful” and push the boundaries of what lighting can do by blending design, and utility. To learn more about Govee, please visit govee.com.

About the Miami Dolphins

The Miami Dolphins, owned by Chairman of the Board & Managing General Partner Stephen M. Ross, are the oldest major-league professional sports franchise in the state of Florida. The team began playing in 1966 and joined the NFL with the AFL-NFL merger in 1970. The franchise has won two Super Bowls – in the 1972 (VII) and 1973 (VIII) seasons – five conference championships and 13 division titles. The Dolphins remain the only franchise in NFL history to complete an undefeated season, going a perfect 17-0 in 1972. The team plays home games at Hard Rock Stadium and trains at the Baptist Health Training Complex in Miami Gardens. For more information, visit MiamiDolphins.com.

Newborn Town Achieves Nearly RMB 5 Billion in Revenue for First Three Quarters, Marking over 37% Year-on-Year Growth

HONG KONG, Oct. 23, 2025 /PRNewswire/ — Newborn Town Inc. (09911.HK), a leading global social entertainment company, released its unaudited operating data for the first three quarters of 2025.

For the nine months ended 30 September 2025, the company’s total revenue is estimated to reach approximately RMB 4,910 million to RMB 4,990 million, reflecting a year-on-year increase of approximately 37.6% to 39.9%.

Among the total revenue, social networking business contributed approximately RMB 4,380 million to RMB 4,440 million, up approximately 34.5% to 36.4% year-on-year. The innovative business saw a year-on-year growth of about 69.9% to 76.3% to approximately RMB 530 million to RMB 550 million, continuing the overall strong growth momentum.


Continuous Breakthroughs in Social Networking Business Driven by AI 

According to the announcement, the significant year-on-year revenue growth in the first three quarters primarily stems from the company’s use of AI technology to drive steady growth in diversified social products. This sustained high growth fully demonstrates the company’s ability to capture user needs precisely and the immense growth potential of the AI-empowered social product matrix.

In the first three quarters, the company’s core products have continuously boosted their competitiveness in the MENA market. Through bolstering product capabilities and operational precision, improving content ecosystems and community ambiance, it has built solid competitive barriers, steadily elevating the competitiveness of their products in this region.

According to Sensor Tower, from January to September 2025, SUGO ranked 6th on the revenue leaderboard for social networking apps in the MENA region, while TopTop ranked 9th on the MENA’s Google Play games app revenue leaderboard.

In 2025, the social entertainment industry in the MENA region continues to exhibit enormous commercial potential. CLSA research report mentioned that there has been ample room for growth in MENA and believes Newborn Town is among the most competitive players to capture these opportunities and expand its market share.

CLSA noted that Newborn Town stands out among peers for its deep user insights, tailored services and diversified monetization model; it has demonstrated powerful competitive edge in product features innovation, traffic acquisition and content operations capability thanks to its strong local presence.

In addition, the application of AI technology in business scenarios has become increasingly in-depth. By deepening AI applications in key areas such as content recommendations and user matching, Newborn Town continues to enhance product experiences and operational efficiency.

In September, the company signed a strategic cooperation agreement with Tencent Cloud, with both parties leveraging their respective strengths to jointly explore the vast space of “AI + social entertainment.”

Strong Growth in Innovative Business with Revenue Exceeding 70%

The innovative business has demonstrated strong development momentum in the first three quarters in 2025. The announcement shows that the high growth was mainly attributable to the steady development of traffic monetization and social e-commerce business, as well as the initial revenue contribution from the actively-invested short drama business. In addition, quality games products have also contributed revenue.

Since Q4 2024, the company’s quality game business has officially entered its payback period. Flagship games represented by Alice’s Dream: Merge Games have entered the long-term operation phase, and the new game development has been progressing smoothly, expected to yield greater growth momentum in the future.

Meanwhile, the social e-commerce business has maintained steady growth, further consolidating Heer Health’s leading position in the health services segment.

Additionally, Aippy, the AI-powered creative content community launched earlier, has become part of the key forward-looking plan in the “AI + Social Entertainment” sector. Its iOS version is now available for download.

In the first half of the year, Newborn Town established its global headquarters in Hong Kong, marking a new stage in the company’s globalization process.

Going forward, the company’s global headquarters will collaborate efficiently with its MENA regional headquarters in Riyadh, Saudi Arabia, and the Southeast Asia regional headquarters in Singapore.

Together with over five R&D centers and more than 20 operational centers worldwide, this model will inject new momentum into the company’s long-term, high-quality global development.

 

HKPC Releases “AI Readiness in Workplace Survey 2025” AI Adoption Approaches 90%, Talent Shortage is the Biggest Challenge; Eight Key Recommendations to Deeply Integrate AI with Industry Digital Transformation


HONG KONG SAR – Media OutReach Newswire – 23 October 2025 – The Hong Kong Productivity Council (HKPC) today released the results of the “AI Readiness in Workplace Survey 2025”, which delves into the overall readiness, actual needs, challenges and future development opportunities of local enterprises in the application of artificial intelligence (AI). Building on these insights, HKPC set out eight strategic recommendations to drive broad and deep integration of AI across industries and to accelerate enterprise digital transformation.

As AI emerges as the core engine of a new wave of industrial transformation, the HKSAR Government’s latest Policy Address explicitly designates AI as a pillar industry for Hong Kong’s future development. In light of this trajectory, local enterprises face mounting urgency to accelerate AI deployment, embed AI into core operations, and build sustainable, AI-driven competitiveness. To assess the current state of adoption, the HKPC Academy, under HKPC, conducted a survey in September 2025, successfully interviewing around 800 local companies. The major findings are as follows:

AI Applications Enter a New Phase: From Tool Trials to Full Integration

AI technology is moving from initial trials to comprehensive integration and has become an important support for enterprises’ digital transformation and strategic upgrades.

  • Widespread use of AI tools: 88% of employees in surveyed companies have already used AI tools in their day-to-day work, mainly in customer service, data analysis, and marketing.
  • Integrating AI into Formal Workflows: 92% of respondents plan to gradually introduce AI into related workflows in the future, with 24% planning to fully implement it within one year, indicating a strong willingness to drive adoption.
  • Institutional and Governance Framework Development: 45% of the surveyed enterprises already have officially recognised AI platforms for employees to use, and more than half (54%) of them said they do not have a complete or ongoing AI governance framework or policy for the time being.
  • Recognition of application benefits: Respondents believe that AI can help increase productivity, reduce production costs, improve decision-making, and enhance customer experience.

Enterprises Face Five Major Challenges in AI Application: Talent Gap and Data Security as Core Obstacles

Despite the increasing popularity of AI technology applications, enterprises still face multiple challenges in practice:

  1. Lack of AI Expertise and Training: Talent development lags technology, becoming the top hurdle to AI rollout.
  2. Data Privacy and Security Concerns: Enterprises have concerns about data handling, regulatory compliance, and risk management.
  3. Difficulty in Integrating with Existing Systems: Incompatible technical architectures leads to complex and costly deployments.
  4. Employee Resistance or Readiness Gaps: Weak digital culture and limited awareness of transformation contribute to slow implementation.
  5. High Implementation Costs: Cost pressures are particularly significant for SMEs with limited resources, impacting their willingness to adopt.

“Three Directions and Eight Actions” Lead Enterprises to Accelerate the Implementation of AI Applications

To address the above challenges, HKPC has put forward eight recommendations to plan a systematic AI transformation roadmap for enterprises, from human resources, strategic layout to organisational culture:

Establishing AI Foundations:
1. Develop a clear AI development strategy and long-term plan.
2. Strengthen leadership from the top and cross-departmental collaboration to establish a top-down transformation promotion mechanism.
3. Establish a data governance and security compliance framework, along with a trusted AI application foundation

Deepening Operational Integration:
4. Implement AI skills training for all employees and cultivate a digital organisational culture.
5. Promote the integration of AI systems with internal corporate systems to lower technical barriers.
6. Deeply embed AI tools into business processes to improve operational efficiency.

Achieving Sustainable Impact:
7. Implement the “One Enterprise, One AI Coach” Scheme to empower AI professionals to continuously promote AI training and application within the organisation.
8. Establish an AI investment return assessment and optimization mechanism.

Dr Lawrence CHEUNG, Chief Technology Officer of HKPC, said, “In the digital economy era, AI has become an indispensable core pathway driving digital transformation for enterprises. Its application has shifted from being the domain of the technical department to a necessary skill for all employees. We encourage enterprises to craft a clear AI development blueprint and systematically plan their future technological roadmap and talent strategy. Top-level design should lead business innovation to build sustainable competitiveness. HKPC will continue to play the roles of ‘promoter, connector, implementer, and gatekeeper’ to facilitate the deep integration of AI with industry. In the future, we will connect the four key elements of ‘standards, technology, talent, and scenarios’ to ensure that AI applications are responsible, scalable, and sustainable. Through demonstrative guidance, we aim to drive intelligent upgrades in the industry and help Hong Kong become a global AI+ model city, achieving dual enhancements in the economy and people’s livelihoods.”

HKPC Empowers Enterprises Digitally Transformation with the “AI for All” Initiative

To accelerate the adoption of AI technology, HKPC has officially launched the “AI for All” initiative, which comprehensively enhances the AI application capabilities of enterprise employees and the public through training empowerment, technical support and industry collaboration, and assists enterprises in their digital transformation. Internally, HKPC is leading the way in cultivating an AI culture, providing over 6,000 hours of AI training to employees, with an average of 5.5 hours of training per person. Various departments have actively promoted over 100 internal AI application projects and developed the innovative AI tool “HKPC Picasso”, which has effectively improved internal work efficiency and provided a transformation model for the industry.

In terms of enterprise AI skills support, HKPC assists enterprises in establishing AI governance frameworks and compliance guidelines, providing clear standards for data security, privacy protection, and ethics across the industry. On the other hand, the HKPC Academy systematically promotes talent cultivation, provides professional courses, qualification certifications, and capacity improvement programs, and continues to provide AI professionals to the industry to improve the industrial ecosystem. Over the past two years, HKPC Academy has provided over 500 AI-related training activities, training approximately 22,000 people, reflecting the high demand for AI skills in the market. Currently, HKPC Academy offers more than 20 AI courses, teaching practical AI combat skills from simple to deep. In order to support the learning of corporate employees, those who enroll in designated online courses can receive an additional nine online courses. HKPC Academy will also collaborate with leading technology companies to invite instructors with practical experience to teach and launch a series of free AI activities to help corporate employees and the public master AI skills.

In terms of industrial applications, HKPC actively aligns with Government policy objectives, formulates a clear roadmap for AI+ development for enterprises, and verifies the effectiveness of the technology through scenario pilots. To lower the entry threshold for enterprises, HKPC not only provides “lightweight, low-threshold” AI solutions covering applications such as customer service automation, document intelligence, and demand forecasting, but also integrates around 250 digital solutions from the Mainland and Hong Kong , along with numerous application cases through the “Digital DIY” platform, providing SMEs and individuals with around intuitive technical references and implementation paths, helping enterprises quickly achieve initial transformation. At present, AI technology has achieved concrete results in three major areas: the introduction of visual inspection and predictive maintenance in the field of smart manufacturing to improve production capacity and yield; In the field of cyber security, AI attack and defense drill platforms are used to strengthen enterprise protection capabilities; In the field of smart city, data analysis is used to optimise the efficiency of transportation, environment, and public services.

In conjunction with the release of this survey, the HKPC Academy held the “HR + L&D Mixer” event on the same day, with the theme of “Redesigning Work and Employee Experience in the Age of AI”. The event invited 100 leaders from human resources, technology, and industry to discuss the impact of AI on job design, talent development, and future skills, promoting companies to strengthen employee experience and cultural construction during transformation.

For High resolution photo and presentation deck, please click here

Hashtag: #HKPC

The issuer is solely responsible for the content of this announcement.

About the Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity through relentless drive of world-class advanced technologies and innovative service offerings to support Hong Kong enterprises. As a nationwide leader in innovative, market-driven research and development (R&D), specialising in leading technologies and all-rounded manufacturing services, HKPC promotes new industrialisation in Hong Kong and the Chinese Mainland and facilitates the development of new productive forces, leveraging innovation and technology (I&T), as well as bolstering Hong Kong to be an international innovation and technology centre and a smart city. The Council offers comprehensive innovative solutions for Hong Kong industries and enterprises to enhance competitiveness. To further support businesses in expanding into global markets, HKPC has established “The Cradle – Go Global Service Centre”, providing essential services to address businesses’ needs in product development, technology, manufacturing, and management, empowering enterprises to successfully go global. The Council partners and collaborates with local industries and enterprises and world-class R&D institutes to promote technology transfer, product innovation, and commercialisation through product innovation, technology transfer, creating value for industries. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades.

In addition, HKPC offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment, and strengthens talent nurturing and Hong Kong’s competitiveness with FutureSkills training for enterprises and academia to enhance digital capabilities and STEM competencies.

For more information, please visit HKPC’s website: .

About HKPC Academy
The Hong Kong Productivity Council (HKPC) has established the Productivity Training Institute in 2004 and upgraded to the HKPC Academy in 2018 to nurture local talent with FutureSkills. By offering innovative, diversified and value-added industry training activities, exhibitions, events and seminars, so as to upgrade the knowledge and skills of practitioners in the industry, enlarge the I&T talent pool, and accelerate Hong Kong’s transformation into an international I&T hub and a smart city.

To promote the I&T culture and overall I&T atmosphere in the community, HKPC Academy works closely with the academia and TechEd partners to offer a wide range of FutureSkills and TechEd training programmes.

For more information on training programmes, please visit: or contact the HKPC Academy.

JeryL Lee Performs at the Chery International User Carnival, Composing a Symphony of Elegance with LEPAS

WUHU, China, Oct. 23, 2025 /PRNewswire/ — On October 21, the 2025 Chery International User Summit reached new heights as Malaysian pop star JeryL Lee made an elegant appearance at the Chery International User Carnival, arriving in the LEPAS L8 and delivering a stunning performance. Ybg. Mr. NG KAI SENG, Minister-Counsellor of the Embassy of Malaysia in China, also attended, witnessing LEPAS’s interpretation of Elegant Driving and a key moment in its global journey.

Partnering with Popular Singer JeryL Lee, LEPAS Accelerates Its Elegant Driving Journey Across Southeast Asia
Partnering with Popular Singer JeryL Lee, LEPAS Accelerates Its Elegant Driving Journey Across Southeast Asia

As one of Southeast Asia’s most acclaimed new-generation singers, JeryL Lee—with her pure voice and radiant image—perfectly embodies the LEPAS philosophy of Drive Your Elegance.” During the Carnival Music Festival, she performed three of her hit songs, igniting the crowd and pushing the event to its climax. Music, technology, and mobility merged seamlessly, expressing LEPAS’s positioning as the Preferred Brand for Elegant Mobility Life.” JeryL also visited the world’s first LEPAS Elegant Lifestyle House, experiencing the brand’s vision of being not only a mobility partner but also a symbol of urban elegance accompanying users in every moment.

Her exclusive ride—the LEPAS L8—captivated attention throughout the event. As LEPAS’s flagship model, it embodies the brand’s three core values: Leopard Aesthetics, Elegant Driving, and Exquisite Space. Inspired by the grace and strength of the leopard, the LEPAS L8 features dynamic body lines and signature lighting details that reflect the spirit ofElegance is Power.”Inside, the skyline-inspired cabin merges refined materials with intelligent technology, creating a luxurious yet functional mobility space for global urban elites. With a wading depth of 600mm, the LEPAS L8 easily handles Southeast Asia’s frequent rain and flooding, offering confident, elegant travel across the region.

As Chery Group’s new energy brand, LEPAS is rapidly expanding in Southeast Asia under the global visionIn somewhere, For somewhere, Be somewhere.”On October 17, during the summit, LEPAS signed partnership agreements with five Indonesian dealerships. Going forward, LEPAS will continue to enhance its presence and deliver elegant, sustainable mobility solutions across Southeast Asia, reinforcing its position as the Preferred Brand for Elegant Mobility Life.

CaoCao Inc. Unlocks Cross-Border Ride-Hailing Service: One App, Six Countries, Ten Cities, Zero Hassle

HONG KONG, Oct. 23, 2025 /PRNewswire/ — Recently, CaoCao Inc. (‘CaoCao’ or ‘Company’ , stock code: 2643.HK) released an overseas ride-hailing guide and launched overseas mobility services in multiple countries and regions. The service initially covers 10 popular tourist cities across 6 countries—Singapore, South Korea, Malaysia, Thailand, the Philippines, and Vietnam, as well as Hong Kong SAR. This means Chinese domestic users no longer need to download additional local ride-hailing apps; they can directly hail taxis overseas via the CaoCao mobility app, which significantly simplifies the overseas travel process.


Now, users only need to open the CaoCao mobility app and switch their location to the aforementioned service-supported countries and regions to enjoy “one-stop ride-hailing  freedom”. Take Singapore as an example: if users travel there for a winter vacation, all their local transportation needs, such as traveling between Changi Airport and hotels, visiting famous attractions like Merlion Park, or exploring Nanyang cuisine in Geylang, can be met through the CaoCao mobility.

According to the latest 2025/2026 Tourism Trends Report released by ITB CHINA, the number of outbound trips made by Chinese mainland residents exceeded 145 million in 2024, and the number of Chinese mainland residents traveling to destinations worldwide is expected to keep growing in 2025. Against this industry backdrop, the demand of domestic tourists for “convenient and localized” overseas mobility services has become increasingly prominent. Previously, Chinese tourists often encountered problems such as language barriers, incompatible payment methods, and unfamiliarity with operations when using local ride-hailing apps overseas. CaoCao Inc.’s overseas mobility service addresses these pain points precisely.

CaoCao stands as a pivotal element in Geely’s future mobility strategy. The company currently covers 163 cities across China, with an average of 38.1 million monthly active users (MAU). With over 37,000 purpose-built vehicles in operation across more than 30 cities nationwide, it has become the biggest technology-driven mobility platform listed on the Hong Kong Stock Exchange. The newly launched overseas mobility service features a unified Chinese interface and real-time Chinese online translation. It also enables RMB mobile payment methods aligned with domestic users’ routines, so there’s no need for extra foreign currency exchange or linking overseas payment tools to the app. As a leading ride-hailing app in China, its branded services have further upgraded the ride-hailing experience abroad.

As the international market thrives, CaoCao Inc. has rolled out its overseas mobility service first in cities like Hong Kong SAR, Singapore, Seoul, Busan, Jeju, Kuala Lumpur, Kota Kinabalu, Bangkok, Ho Chi Minh City and Pasay. It also plans to expand further into popular destinations worldwide. The convenience of “one-stop” ride-hailing service, together with the company’s rich experience of mobility services in China, not only provide Chinese travelers with worry-free and secure international mobility services, but also allow more local residents to access and experience the convenience offered by this Chinese mobility app.

 

HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology

  • Prestigious peer-review validates HCB101’s differentiated mechanism and translational strength.
  • Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono)

TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology (SCI Impact Factor 40.4; for reference, leading journals in the field of immuno-oncology include Journal of Clinical Oncology (impact factor 41.9), The Lancet Oncology (35.9), and Nature Cancer (28.5)).

The publication, titled “HCB101: A Novel Potent Ligand-Trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors,” describes the rational protein engineering that enabled HCB101 to restore macrophage-mediated phagocytosis and bridge innate and adaptive immune responses while reducing red blood cell binding. In preclinical studies, HCB101 showed broad activity across more than 80 xenograft and PDX tumor animal models with a safety profile that differs from first- and second-generation CD47-targeting agents.

HanchorBio’s CD47-SIRPα Therapeutic HCB101 Published in Journal of Hematology & Oncology, Demonstrating High Safety and Preclinical Efficacy
HanchorBio’s CD47-SIRPα Therapeutic HCB101 Published in Journal of Hematology & Oncology, Demonstrating High Safety and Preclinical Efficacy

Notably, a US competitor focusing on CD47/SIRPα published findings in JHO in November 2020, reporting on a third-generation anti-CD47–SIRPα therapy. This underscores the journal’s strong recognition within the field. The continued publication of anti-CD47 biologics in JHO highlights both the scientific importance of ongoing advancements and the journal’s role as a leading international platform for preclinical and translational research on anti-CD47 therapies.

“Publication in the Journal of Hematology & Oncology affirms the scientific rigor and innovation behind HCB101 and emphasizes its differentiated preclinical foundation,” said Scott Liu, PhD, Chairman, CEO, and Founder of HanchorBio. “Importantly, these insights are being directly translated into clinical studies: combined with standard-of-care, HCB101 has demonstrated a clear dose-dependent efficacy profile in 2L gastric cancer, culminating in a nearly 90% partial response rate at 5.12 and 8.0 mg/kg. In parallel, we have now escalated monotherapy dosing to 30 mg/kg without safety concerns. These milestones highlight HCB101’s potential to serve as a backbone immunotherapy across solid tumors and hematologic malignancies and lay the groundwork for expanding into autoimmune indications where CD47-SIRPα biology is also potentially useful in creating a new B-cell depletion therapy.”

Clinical Progress Strengthens Differentiated Best-in-Class Profile
HCB101 is currently being evaluated in multinational Phase 1 and Phase 1b/2a trials:

  • Monotherapy (HCB101-101, NCT05892718):
    The Safety Review Committee (SRC) has reviewed the safety data up to 30 mg/kg weekly and found no dose-limiting toxicities, confirming a wide therapeutic window. Early signs of efficacy included two confirmed partial responses (PRs) in head and neck squamous cell carcinoma and marginal zone lymphoma, along with stable disease (SD) in nine patients, including over 40 weeks of disease control in platinum-resistant ovarian cancer.
  • Combination (HCB101-201, NCT06771622):
    In the triplet regimen for 2L-gastric cancer (HCB101 + ramucirumab + paclitaxel), emerging activity was first observed at 2.56 mg/kg, where evaluable patients achieved SD with modest tumor shrinkage, averaging a 6% reduction in tumor size in the dose cohort. At 5.12 mg/kg, all three evaluable patients achieved confirmed PRs (33%–46% tumor reductions). At 8.0 mg/kg, all three evaluable patients have now achieved confirmed PRs (tumor shrinkage up to -78%) after extended follow-up. Together, these results represent a nearly 90% confirmed response rate (6 of 7 patients) at ≥ 5.12 mg/kg dose level — a striking outcome in a setting where the typical overall response rate (ORR) for the SOC is only 26.5%.

“The data now published in JHO validate the design strategy that made HCB101 possible – balancing high efficacy with a clean safety margin where earlier CD47-targeting agents failed,” added Wenwu Zhai, PhD, Chief Scientific Officer of HanchorBio. “Seeing those preclinical insights translate into durable monotherapy activity and remarkable combination dose-dependent responses in gastric cancer provides confidence not only for oncology but also for new areas such as autoimmunity. HCB101’s differentiated mechanism and safety profile open the door to rational combinations and next-generation applications well beyond cancer.”

About HCB101: A Differentiated CD47-SIPRα Blockade
HCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with intact IgG4 effector function, developed using HanchorBio’s proprietary FBDB™ platform. Engineered for selective CD47 blinding on tumors with low affinity for red blood cells, HCB101 avoids the hematologic toxicities commonly associated with anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging.

Key Differentiators of HCB101:

  • Enhanced safety: Low RBC binding minimizes anemia and thrombocytopenia risk.
  • Robust immune activation: Engineered to enhance ADCP and innate-to-adaptive bridging.
  • Broad tumor applicability: Demonstrated activity in >80 PDX/CDX preclinical models.
  • Clinical translation: Early efficacy as monotherapy with durable disease control, and 100% ORR and disease control rate (DCR) at the middle dose cohort in combination with standard-of-care for 2L-gastric cancer.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and international development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: www.HanchorBio.com

Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific

With a strong track record across APAC, Francis Wan’s appointment marks a powerful acceleration of Medison’s growth in the region

ZUG, Switzerland, Oct. 23, 2025 /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization platform for breakthrough therapies, today announced the appointment of Francis Wan as VP, GM Asia Pacific (APAC) and member of the company’s Global Leadership Team.

From left to right: Meir Jakobsohn, Executive Chairman Medison, Francis Wan, VP GM APAC,Victor Papamoniodis, Chief Commercial Officer, Gil Gurfinkel, CEO
From left to right: Meir Jakobsohn, Executive Chairman Medison, Francis Wan, VP GM APAC,Victor Papamoniodis, Chief Commercial Officer, Gil Gurfinkel, CEO

Francis will lead Medison’s strategy and operations across the APAC region, a critical growth area for the company’s platform. With more than 20 years of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His expertise in rare disease and oncology, together with his extensive experience in China’s healthcare landscape, adds a vital dimension to Medison’s strategy for the region.

“Across APAC, breakthrough therapies are still out of reach for many patients, leaving a vast and diverse population with significant unmet needs,” said Francis Wan. “Through Medison’s global commercialization platform, we have a unique opportunity to change this reality and expand access to breakthrough therapies. Having spent much of my career in China and across APAC, I understand firsthand how essential it is to deliver sustainable solutions and enable faster access for patients with rare and severe diseases.”

“Medison was founded on the belief that every patient, no matter where they live, deserves timely access to breakthrough therapies,” said Meir Jakobsohn, Founder and Executive Chairman of Medison. “Francis’s appointment reflects our continued investment in APAC and marks an important step in accelerating additional growth in the region, a region with enormous need and opportunity.”

“Francis joining Medison is another important milestone in our global growth journey,” said Gil Gurfinkel, CEO of Medison. “With his appointment, we continue to advance toward completing our expansion roadmap and building a world leader and the best commercialization company for international markets. Francis’s extensive experience with healthcare systems and his proven record of creating access and commercial success in China and across APAC will strengthen our ability to accelerate access to life-changing therapies and deepen our partnerships in the region and on a global scale.”

“Francis brings outstanding expertise and a proven track record in establishing and scaling biopharma operations in China and the broader APAC region,” said Victor Papamoniodis, Chief Commercial Officer at Medison. “His leadership will be instrumental in scaling our platform and expanding patient access to breakthrough therapies in APAC.”

About Medison
At Medison, we are addressing one of the pharma industry’s most pressing challenges: enabling access to breakthrough therapies for patients with severe and rare diseases in international markets where traditional commercialization models fall short. 

As the creator and leader of the global partnership category, we have built a first-of-its-kind unified commercialization platform that enables biotechs to effectively plan, optimize and launch their therapies on a global scale. 

With a strong leadership team and a proven track record, we are the partner of choice for innovative biotech companies seeking to expand beyond the US, Western Europe and Japan into regions where most of the world’s population resides. Our affiliate-like model integrates commercial, medical and operational capabilities across diverse geographies, accelerating access and delivering life-changing treatments to more patients, faster. 

Medison is on a mission to ensure that every patient, regardless of where they live, has the opportunity to benefit from breakthrough therapies. 

For more information, please visit https://www.medisonpharma.com/

Contact:
Margo Corn Ladani 
Senior Manager, Global Communications 
T:  +972 52 6606710
E: MargoC@medisonpharma.com

 

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) that, for the first time, include the use of Telix’s investigational PET[1] agent, TLX250-CDx (Zircaix®[2]89Zr-DFO-girentuximab), for molecular imaging of renal masses.

Published on the SNMMI website[3] and in The Journal of Nuclear Medicine[4], the guideline panel[5], comprising internationally renowned and multidisciplinary expert key opinion leaders, concludes that “the emerging use of molecular imaging for risk stratification of indeterminate renal masses offers the opportunity to more effectively characterize such lesions and optimize patient management decisions”.

The panel asserts that antibody-based radiotracers exhibit lower renal clearance, thereby improving visualization of renal masses. It emphasizes that TLX250-CDx PET “appears to be a well-tolerated and accurate method for non-invasive identification of ccRCC[6]” and notes by contrast, the high renal excretion with 18F-FDG PET, which obscures accurate lesion detection.

The panel references data from Telix’s pivotal Phase 3 ZIRCON trial[7], which met all primary and secondary endpoints, demonstrating a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[8]. TLX250-CDx works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on >95% of ccRCC cells[9], to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.

Professor Brian Shuch, MD, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA Institute of Urologic Oncology and guideline author, commented, “The recognition of ⁸⁹Zr-girentuximab PET in the SNMMI/EANM/ACNM clinical guidelines reflects a shift toward precision medicine in renal cancer, providing clinicians with a more accurate tool for diagnosis to guide optimal, individualized treatment planning for patients.”

Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, added, “The inclusion of TLX250-CDx PET imaging for the first time in SNMMI/EANM/ACNM guidelines is an important development for Telix and will help raise awareness of this breakthrough precision diagnostic. Subject to regulatory approval, endorsement by this expert global multidisciplinary panel will help to drive adoption and implementation into clinical workflows, supporting clinical utility and enhancing decision-making to improve patient outcomes.”

SNMMI, EANM and ACNM periodically define new procedure standards/guidelines to help advance the science of nuclear medicine and to improve the quality of service to patients. Each standard/guideline, representing a policy statement by these groups undergoes a thorough consensus process in which it has been subjected to extensive review.

About TLX250-CDx

TLX250-CDx is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% PPV for ccRCC across three independent radiology readers. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC.

For more on TLX250-CDx and Telix’s theranostic kidney cancer program, click here.
TLX250-CDx has not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA[10].

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
Eliza@schleifsteinpr.com

Legal Notices
Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1] Positron emission tomography.
[2] Brand name subject to final regulatory approval.
[3] https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2025/SNMMI_EANM _ACNM_Renal_Masses-Final%20JNM%20sumbission.pdf
[4] SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization (October 2025), available at: https://jnm.snmjournals.org/content/early/2025/10/09/jnumed.125.271332.abstract
[5] Steven P. Rowe, Brian M. Shuch, Mark W. Ball, Axel Bex, Mehrbod S. Javadi, Alan Klitzke, Karolien Goffin, Peter Mulders, Neeta Pandit-Taskar, Ashwin Singh Parihar, Benjamin L. Viglianti, Michael A. Gorin, and Ken Herrmann.
[6] Clear cell renal cell carcinoma, the most common and one of the most aggressive subtypes of kidney cancer.
[7] ClinicalTrials.gov ID: NCT03849118.
[8] Telix ASX disclosures 7 November 2022. Shuch et al. Lancet Oncology. 2024.
[9] Stillebroer et al. Eur Urol. 2010.
[10] Telix ASX disclosure 21 March 2025.